📊 CLGN Key Takeaways
Is CollPlant Biotechnologies Ltd (CLGN) a Good Investment?
Insufficient financial data available for fundamental analysis. SEC EDGAR filings show no disclosed revenue, profitability metrics, or balance sheet details for the latest reporting period. Cannot assess financial health, operational performance, or growth trajectory without core financial statements.
CollPlant’s fundamentals remain weak: the business is still deeply unprofitable, revenue is small and highly lumpy, and recent growth has been driven mainly by milestone payments rather than durable commercial demand. The balance sheet is cleaner than many early-stage biotechs because debt is minimal and cash was $8.5 million as of September 30, 2025, but ongoing operating burn and dependence on partner progress still point to financing risk and low earnings quality.
Why Buy CollPlant Biotechnologies Ltd Stock? CLGN Key Strengths
- Listed on Nasdaq exchange indicating some regulatory compliance
- Operating in orthopedic/surgical appliances sector with potential market applications
- SEC registered company with public disclosure requirements
- Debt-light balance sheet with total liabilities of about $4.8 million versus $9.3 million of equity as of September 30, 2025
- Operating cash burn improved to $6.5 million for the first nine months of 2025 from $10.6 million in the prior-year period
- AbbVie collaboration continues to provide milestone-driven revenue potential and external validation of the platform
CLGN Stock Risks: CollPlant Biotechnologies Ltd Investment Risks
- Complete absence of revenue and profitability data suggests pre-commercial or distressed financial condition
- No balance sheet metrics available to assess liquidity or solvency
- No cash flow data available; unable to evaluate operational sustainability or capital requirements
- Zero insider trading activity in last 90 days suggests limited management confidence or activity
- Extremely limited data quality with only 1 metric available out of comprehensive suite
- Revenue quality is weak because 2025 revenue growth was driven mainly by a $2 million AbbVie milestone, not broad recurring commercialization
- The company remains loss-making with a net loss of $8.3 million for the first nine months of 2025 and a large accumulated deficit
- Cash runway appears limited relative to burn, increasing the likelihood of additional capital raises or deeper cost cuts if milestones slip
Key Metrics to Watch
- Revenue recognition and gross margin upon commercialization
- Cash burn rate and liquidity position relative to runway
- Clinical trial progress and regulatory milestones for product portfolio
- Quarterly operating cash burn versus cash balance/runway
- Recurring product revenue excluding collaboration and milestone payments
CollPlant Biotechnologies Ltd (CLGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CLGN Profit Margin, ROE & Profitability Analysis
CLGN vs Healthcare Sector: How CollPlant Biotechnologies Ltd Compares
How CollPlant Biotechnologies Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CollPlant Biotechnologies Ltd Stock Overvalued? CLGN Valuation Analysis 2026
Based on fundamental analysis, CollPlant Biotechnologies Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CollPlant Biotechnologies Ltd Balance Sheet: CLGN Debt, Cash & Liquidity
CLGN Revenue Growth, EPS Growth & YoY Performance
CLGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CollPlant Biotechnologies Ltd (CIK: 0001631487)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLGN
What is the AI rating for CLGN?
CollPlant Biotechnologies Ltd (CLGN) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 48% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLGN's key strengths?
Claude: Listed on Nasdaq exchange indicating some regulatory compliance. Operating in orthopedic/surgical appliances sector with potential market applications. ChatGPT: Debt-light balance sheet with total liabilities of about $4.8 million versus $9.3 million of equity as of September 30, 2025. Operating cash burn improved to $6.5 million for the first nine months of 2025 from $10.6 million in the prior-year period.
What are the risks of investing in CLGN?
Claude: Complete absence of revenue and profitability data suggests pre-commercial or distressed financial condition. No balance sheet metrics available to assess liquidity or solvency. ChatGPT: Revenue quality is weak because 2025 revenue growth was driven mainly by a $2 million AbbVie milestone, not broad recurring commercialization. The company remains loss-making with a net loss of $8.3 million for the first nine months of 2025 and a large accumulated deficit.
What is CLGN's revenue and growth?
CollPlant Biotechnologies Ltd reported revenue of N/A.
Does CLGN pay dividends?
CollPlant Biotechnologies Ltd does not currently pay dividends.
Where can I find CLGN SEC filings?
Official SEC filings for CollPlant Biotechnologies Ltd (CIK: 0001631487) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLGN's EPS?
CollPlant Biotechnologies Ltd has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CLGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, CollPlant Biotechnologies Ltd has a SELL rating with 48% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CLGN stock overvalued or undervalued?
Valuation metrics for CLGN: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CLGN stock in 2026?
Our dual AI analysis gives CollPlant Biotechnologies Ltd a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLGN's free cash flow?
CollPlant Biotechnologies Ltd's operating cash flow is N/A, with capital expenditures of N/A.
How does CLGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).